"The guests argued that buying companies at 70% or less of their private market value—validated by real M&A comps and an absolute cheapness overlay—protects capital and drives long-term outperformance."

"The thesis presented suggests favoring diversified healthcare ETFs over individual high-flying biotech stocks that have already experienced massive run-ups."